Introduction: Zika virus (ZIKV) has emerged as a major global public health concern in the last years due to its link as a causative virus of congenital neurological disease. In countries where there is a circulation of other arboviruses, such as Dengue and Chikungunya, such as Brazil, the clinical diagnosis of ZIKV infection becomes extremely difficult since the signs and symptoms are very similar. Therefore, laboratory diagnosis is of fundamental importance. Currently, the reverse transcriptase reaction followed by quantitative polymerase chain reaction (qRT-PCR) is the gold standard for molecular diagnostic of ZIKV in human samples. However, the technique presents high cost and limitations for Point-of-care (POC) diagnostics. Given the lack of approved vaccines and antivirals against ZIKV, rapid and reliable POC diagnostic test for detection of ZIKV is urgently required to facilitate initiation of control and preventive measures, especially for pregnant women who are at a risk of infection, as well as to increase the diagnostic capacity of ZIKV-affected low-resource scenarios.
